FIELD: pharmaceutics.
SUBSTANCE: invention refers to pharmaceutical industry and represents pharmaceutical composition including mixture of: (a) simeticon, from 10 to 20 wt.% of composition weight, (b) calcium phosphate powder, 20 to 40 wt.% of composition weight, and (c) mannitol, from 30 to 50 wt.% of composition weight, where weight ratio of mannitol to calcium phosphate powder is at least 1:1.
EFFECT: invention provides synergetic effect, which consists in high stability against disintegration in stress conditions, as well as excellent fluidity and compressibility properties.
12 cl, 2 ex, 3 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| TABLET FOR ORAL ADMINISTRATION FOR INDUCED SALIVA FORMATION | 2019 |
|
RU2782830C2 |
| PHARMACEUTICAL COMPOSITION INCLUDING SODIUM ALKYL SULPHATE | 2019 |
|
RU2759746C1 |
| IMMEDIATE RELEASE PHARMACEUTICAL COMPOSITIONS CONTAINING KETOPROFEN LYSINE SALT | 2019 |
|
RU2804350C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING ROSUVASTATIN CALCIUM SALT (VERSIONS) | 2015 |
|
RU2606592C1 |
| COMPRESSIBLE AND FREE-FLOWING COAGGLOMERATES OF MANNITOL AND GRANULAR STARCH | 2010 |
|
RU2540914C2 |
| COMPOSITION OF SOLID QUICK-DISINTEGRATING TABLET | 2008 |
|
RU2472493C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING DESLORATADINE (VERSIONS) | 2013 |
|
RU2537169C1 |
| CHEWING GUM IN TABLET FORM, SUITABLE FOR ACTIVE PHARMACEUTICAL INGREDIENTS | 2019 |
|
RU2770035C1 |
| PHARMACEUTICAL COMPOSITIONS CONTAINING S1P RECEPTOR MODULATOR | 2007 |
|
RU2487703C2 |
| COMPOSITION SIMETHICONE/ANHYDROUS CALCIUM PHOSPHATE | 1998 |
|
RU2216317C2 |
